Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen monograph amendment

This article was originally published in The Tan Sheet

Executive Summary

Labeling of sunscreen products introduced after Sept. 1 will need to reflect USP name changes for four active ingredients, FDA says in technical amendment published in Federal Register June 20. Changes were proposed by USP in 2000 based on designations approved by U.S. Adopted Names Council. Proposal was accepted in March 2001, becomes effective Sept. 1. New names include meradimate for menthyl anthranilate; octinoxate for octyl methoxycinnamate; octisalate for octyl salicylate; and ensulizole for phenylbenzimidazole sulfonic acid. Comments on amendment will be accepted until Aug. 19...

You may also be interested in...



Sunscreen Ingredient Name Change Required By Sept. 1

FDA will not take enforcement action against sunscreen manufacturers unable to re-label products to reflect required name changes for four ingredients before Sept. 1, the agency said in guidance to industry

Sunscreen Labeling Amendment Would Disrupt Product Supply, Industry Says

A Sept. 1 deadline for amending the names of four sunscreen ingredients on labeling would "unnecessarily disrupt the supply of sunscreen products," the Consumer Healthcare Products Association and Cosmetic, Toiletry & Fragrance Association tell FDA

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Topics

UsernamePublicRestriction

Register

PS094187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel